Access and Evidence
Value: A Balancing Act
When it comes to proving the value of a new medicine, pharma has to strike the right balance
More Access and Evidence Articles
Access and Evidence
Can Payers Trust Our Data?
Analyses from RWD are playing an increasingly important role, but will payers accept pharma’s figures?
Access and Evidence
Diving for Data
Finding the right data to underpin outcome-based contracts is not as easy as it looks
Access and Evidence
Rid Yourself Of Dirty Data
Real-world data holds enormous potential. But it also risks being riddled with bias.
Access and Evidence
Could Digital Medicines Improve Access For All?
Digital medicines could provide a new roadmap to reimbursement and regulatory approval.
Access and Evidence
Talking The Same Language
A universal standard for real-world evidence no longer seems quixotic. But how are companies going to do it?
Access and Evidence
Going Through the Motions
Both pharma and payers say they need to talk more, but are they really listening?
Access and Evidence
Navigating the Chaos
With the access landscape shifting rapidly, pharma needs to watch its step
Access and Evidence
Seeking the Holy Grail of RWE
Universal standards for real-world evidence are closer than you might think
Access and Evidence
United: How employers are changing healthcare
The growth in employer coalitions are a sign that plan sponsors are increasingly flexing their muscles, but what do they hope to achieve?